JPH0881372A - Preventive/therapeutic agent for medical symptom due to decrease in erytherocyte number - Google Patents

Abstract

PURPOSE: To obtain a preventive/therapeutic agent containing imidazole compound(s), useful for symptoms due to decrease in erythrocyte number caused by hematopoietic hypofunction or hematozemia, etc. CONSTITUTION: This preventive/therapeutic agent contains at least one kind of imidazole compound selected from anserine, carnosine, balenine, homocarnosine, π-methylhistidine and τ-methylhistidine, or an extract consisting mainly of one or more of them. This agent can be conventionally subjected to pharmaceutical manufacturing process into a medical agent for oral or parenteral administration, or made into auxiliary foods for medical use. This agent is effective for anemia involved in hematopoietic hypofunction or hematozemia, aplastic anemia, inborn anemia, renal anemia, myelogenous anemia, anemia involved in chronic arthrorheumatism. The anemia involved in hematopoietic hypofunction is e.g. due to the decrease in erythrocyte number by chemotherapeutic agents such as carcinostatics, radiation, stress, etc., while the anemia involved in hematozemia is, e. g. due to operations, blood donation, childirth.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to a medical treatment caused by a decrease in the number of red blood cells containing anserine, carnosine, valenin, homocarnosine, π-methylhistidine, τ-methylhistidine or an extract containing them as a main component. The present invention relates to a preventive or ameliorating agent for symptoms, a food or drink having a preventive or ameliorating effect on medical symptoms caused by a decrease in the number of red blood cells, and a method for producing the same.

[0002]

2. Description of the Related Art Supplementing these deficient nutrients to a patient suffering from anemia due to a deficiency of iron, protein, vitamins, etc. due to continued inadequate intake of quantitatively or qualitatively dietary anemia It is an effective way to improve. However, in recent years, drug treatments such as anticancer agents and radiation treatments,
Alternatively, due to some pathological condition, the hematopoietic function is suppressed, so that anemia often occurs. For such anemia of hematopoietic inhibition, nutritional supplements are rarely effective.

Particularly in clinical practice, it has been a serious problem that anticancer agents and irradiation of radiation induce a decrease in the number of red blood cells and lead to anemia. Although there is a method of transplanting bone marrow cells to such a disorder of inhibiting hematopoietic function, the supply amount of fresh bone marrow cells is limited, and there is a risk of virus contamination. For a wide range of hematological disorders caused by bone marrow disorders such as aplastic anemia and myelodysplastic syndrome, concomitant use with other hematopoietic factors such as granulocyte colony stimulating factor at the same time as bone marrow transplantation is performed. Although the recovery of the red blood cell count is promoted, the recovery of the red blood cell count and the recovery of anemia have not been promoted by shortening the reduction period of the red blood cell count.

[0004] Further, although anemia associated with renal anemia and rheumatoid arthritis has been treated by intravenous injection of erythropoietin, it is a treatment that causes pain because it cannot be administered orally. Therefore, it is desired to develop a safe and orally administrable drug.

On the other hand, L-carnosine (β-alanyl-L
-Histidine), L-anserin (β-alanyl-π-
Methyl-L-histidine) and L-valenin (β-alanyl-τ-methyl-L-histidine) are mammals, birds,
It is a dipeptide existing in muscle tissues such as reptiles and amphibians, and homocarnosine is a known substance as a dipeptide mainly existing in the brain. Many studies have been conducted since these dipeptides were discovered at the beginning of this century, and it has been reported that carnosine, anserine, and varenin are present in vertebrate skeletal muscle in a concentration range of 1 to 20 mM, and the content thereof is muscle. It is known to change with the type and age of animals.

However, in recent years, studies of the action and effect have been carried out, and it was discovered that homocarnosine has a tissue repairing action and an immunomodulating action (Japanese Patent Laid-Open No. 61-145118), and homocarnosine causes nucleic acid biosynthesis. It has been shown to promote and activate diminished tissue repair and immune functions. And in JP-A-1-93526,
It has been disclosed that homocarnosine suppresses leukopenia due to side effects of chemotherapeutic agents and radiation therapy that prevent the growth of cancer and viruses.

In Japanese Patent Publication No. 13928/1993, L
-Carnosine is disclosed to suppress leukopenia, which is a side effect of chemotherapeutic agents with nucleic acid biosynthesis inhibitory activity. Further, in JP-A-61-246218 and JP-B-4-81966, L-anserin and L-carnosine restore abnormal abnormal reduction of immune response and suppress excessive hyperactivity to suppress normal immune system. It is disclosed that it has a function of maintaining the function. There is also a report that when carnosine is administered to mice, the survival rate is increased and the colony formation rate of hematopoietic stem cells is increased when the mice are irradiated (Bull. Exp. Biol. Med. 112 (7).
966-968 (1991)).

On the other hand, in Japanese Unexamined Patent Publication (Kokai) No. 4-187067, carnosine, anserine, and varenin have an antioxidant effect on protein foods.
In JP-A-35-35, carnosine, anserine, and valenin are added so that the product content is 0.1% or more, and the pH is
It is possible to improve the taste of the product by setting the ratio to 6.5 or more, and JP-A-2-35057 discloses a functional food containing a high concentration of L-carnosine.

However, anserine, carnosine, varenin, homocarnosine, π-methylhistidine, τ-
It has not been known at all that methylhistidine has the action of promoting the recovery of the red blood cell count by reducing the decrease in the red blood cell count and shortening the reduction period of the red blood cell count.

[0010]

Therefore, the present invention provides a highly safe agent for preventing or ameliorating a medical condition caused by a decrease in the red blood cell count, as well as preventing or improving a medical condition caused by a decrease in the red blood cell count. It is intended to provide food and drink having an action and a method for producing the same.

[0011]

Means for Solving the Problems As a result of earnest research to solve the above problems, the present inventors have found that anserine,
Carnosine, valenin, homocarnosine, π-methylhistidine, τ-methylhistidine is a preventive effect against a medical condition (for example, anemia) resulting from a decrease in the number of red blood cells caused by hematopoietic function suppression or blood loss. It was found that a recovery promoting effect was exhibited, and the present invention was completed.

Accordingly, the present invention is based on a reduction in the number of red blood cells containing one or more imidazole compounds selected from the group of anserine, carnosine, varenin, homocarnosine, π-methylhistidine, and τ-methylhistidine. The present invention aims to provide a preventive or ameliorating agent for medical symptoms.

The present invention also relates to anserine, carnosine,
Valenin, homocarnosine, π-methylhistidine, and τ-methylhistidine in food and drink substantially containing,
Anserine, carnosine, varenin, homocarnosine,
Prevention of medical symptoms caused by a decrease in red blood cell count, which is obtained by adding one or more imidazole compounds selected from the group of π-methylhistidine and τ-methylhistidine, or an extract containing the same as a main component Or, it relates to a food or drink having an improving effect.

Further, anserine, carnosine, valenin, homocarnosine, π-methylhistidine, and τ-
A food or drink that does not substantially contain methylhistidine, characterized by adding anserine, carnosine, varenin, homocarnosine, π-methylhistidine, and τ-methylhistidine or an extract containing this as a main component. The present invention relates to a method for producing a food or drink having a preventive or ameliorating effect on a medical condition caused by a decrease in the number of red blood cells.

[0015]

[Detailed Description] Anserine, carnosine, varenin, homocarnosine, π-methylhistidine, τ-of the present invention
Methylhistidine was extracted, separated and purified from natural products such as broth discharged during the production of bonito flakes or dried sardines, marine broth such as broth discharged during the production of canned tuna, or livestock meat such as waste chicken. Even one
It may be chemically or enzymatically synthesized, or may be produced by a microorganism.

The anserine, carnosine, valenin, homocarnosine, π-methylhistidine, τ-of the present invention
Methylhistidine may be any of D-form, L-form and DL-form. Since naturally occurring anserine, carnosine, valenin, homocarnosine, π-methylhistidine and τ-methylhistidine are all L-forms, the L-form is preferable when used as a food or drink.

The anserine, carnosine, varenin, homocarnosine, π-methylhistidine, τ-methylhistidine of the present invention may be in the form of a salt, such as anserine salt, carnosine salt, varenin salt, homocarnosine salt, π.
-Methylhistidine salt and τ-methylhistidine salt include a salt based on a carboxylic acid group and an acid addition salt based on an amino group and a pharmacologically acceptable acid, and both a carboxylic acid group and an amino group. There is a salt based on.

Sodium for salts based on carboxylic acid groups,
There are salts with metals such as potassium, calcium, magnesium, zinc and aluminum, ammonium salts and substituted ammonium salts, for example salts with trialkylamines and other amines such as triethylamine, and salts based on amino groups include hydrochloric acid, There are salts with inorganic acids and organic acids such as sulfuric acid, phosphoric acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, succinic acid, maleic acid, benzenesulfonic acid and toluenesulfonic acid, which are known per se. By reacting free anserine, carnosine, homocarnosine, varenin, π-methylhistidine, τ-methylhistidine with a stoichiometrically calculated amount of a selected acid or base. You can These may be used alone or in combination.

In the present invention, the anserine, carnosine, varenin, homocarnosine, π-methylhistidine and τ-methylhistidine of the present invention are not necessarily limited to high-purity purified products, and the imidazole compound of the present invention is used as a main component. It is also possible to use an extract of

The extract containing an imidazole compound as a main component of the present invention means, for example, broth discharged during the production of bonito flakes or dried sardines, and broth of marine products such as broth discharged during the production of canned tuna, Extracts extracted from livestock meat such as abandoned chicken according to the usual method, or broth discharged during the production of bonito flakes or dried sardines or seafood such as broth discharged during the production of canned tuna Examples thereof include a fraction containing the imidazole compound of the present invention separated using an exchange resin or the like. As an example of a preparative purification method, Japanese Patent Laid-Open No. 63-1328
No. 78 publication "Method for preparative separation and purification of dipeptide from bonito broth" is illustrated.

[0021] Particularly, the dipeptide fraction preparatively purified from the broth discharged during the production of canned tuna is rich in anserine, which is preferable. The imidazole compound content of the imidazole compound-based extract of the present invention is 2% or more, preferably 10% or more, more preferably 50% or more, and particularly the anserine content is 1% or more, preferably 5% or more. % Or more, more preferably 20% or more.

The anserine, carnosine, valenin, homocarnosine, π-methylhistidine, τ-methylhistidine of the present invention promotes recovery of erythrocyte count by reducing reduction of erythrocyte count and shortening reduction period of erythrocyte count. Therefore, the imidazole compound of the present invention is useful as a drug or a medical supplement for preventing or ameliorating medical symptoms caused by a decrease in the number of red blood cells caused by suppression of hematopoietic function or blood loss. .

The medical symptoms caused by the decrease in the red blood cell count of the present invention include hematopoietic function-suppressing anemia, blood loss anemia,
Aplastic anemia, congenital anemia, renal anemia, myeloid anemia,
Examples include anemia associated with rheumatoid arthritis, and examples of hematopoietic inhibitory anemia include chemotherapeutic agents such as anticancer agents, irradiation, and anemia caused by a decrease in red blood cell count due to stress, etc. Examples of blood loss anemia include post-operative and post-donation anemias after delivery.

The state in which the number of red blood cells in the blood or the amount of hemoglobin is absolutely decreased is anemia, and pallor of the skin and mucous membranes, palpitation, breathlessness, dizziness, ears, fatigue, head weight,
Symptoms such as cold sensation, swelling, and abnormal taste. As a matter of course, the preventive or ameliorating agent for medical conditions caused by a decrease in the red blood cell count of the present invention is also effective for these conditions. In the present invention, improvement of symptoms is used in a broad sense,
It also includes treatment of diseases.

When the agent for preventing or ameliorating a medical condition caused by a decrease in the number of red blood cells of the present invention is used as a medicine, the dosage form may be any of those which can be conveniently administered orally or parenterally. Injectable solutions, infusion solutions, powders, granules, tablets, capsules, enteric solutions, suppositories, ointments, inhalants, troches, etc. may be used depending on the symptoms. Each can be used alone or in combination. These various formulations
According to a conventional method, the main ingredient can be formulated according to the purpose by using known adjuvants that can be usually used in the technical field of pharmaceutical formulation such as an excipient, a binder, a disintegrating agent, a lubricant, and a corrigent. .

The dose of the preventive or ameliorating agent for medical symptoms caused by the decrease in the red blood cell count of the present invention varies depending on the administration route, dosage form, symptoms, age, body weight, etc. In this case, the total amount of the imidazole compound of the present invention is 50 mg to 5 g / day, preferably 100 mg to 2 g.
/ Day, more preferably 50 mg to 2 g / day, more preferably 50 to 500 mg / day, still more preferably 50 to 180.
mg / day, more preferably 50 to 100 mg / day.

As anserine, 50 mg to 5 g / day,
Preferably 100 mg to 2 g / day, more preferably 50 mg
˜2 g / day, more preferably 50 to 500 mg / day, even more preferably 50 to 180 mg / day, still more preferably 5
0 to 100 mg / day. 50 mg as carnosine
-5 g / day, preferably 100 mg-2 g / day, more preferably 50 mg-2 g / day, more preferably 50 mg-50
It is 0 mg / day, more preferably 50 mg to 180 mg / day, and further preferably 50 mg to 100 mg / day.

As homocarnosine, 50 mg to 5 g /
Day, preferably 100 mg to 2 g / day, more preferably 5
0 mg to 2 g / day, more preferably 50 to 500 mg / day,
The amount is more preferably 50 to 180 mg / day, further preferably 50 to 100 mg / day. Further, as π-methylhistidine, 75 mg to 7.5 g / day, preferably 150 mg to
It is 3 g / day, more preferably 75 mg to 3 g / day, more preferably 75 to 150 mg / day.

Further, as τ-methylhistidine, 75 mg to
7.5 g / day, preferably 150 mg to 3 g / day, more preferably 75 mg to 3 g / day, more preferably 75 to 15
It is 0 mg / day. In the case of parenteral administration, the total amount of the imidazole compound of the present invention is 5 to 500 mg / day, preferably 10 to 200 mg / day, more preferably 5 to 200 mg / day.
The day is more preferably 5 to 50 mg / day, even more preferably 5 to 18 mg / day, still more preferably 5 to 10 mg / day.

As anserine, 5-500 mg / day,
Preferably 10 to 200 mg / day, more preferably 5 to 2
00 mg / day, more preferably 5-50 mg / day, even more preferably 5-18 mg / day, even more preferably 5-10 mg
/ Day. Also, carnosine as 5-500 mg / day,
Preferably 10 to 200 mg / day, more preferably 5 to 2
00 mg / day, more preferably 5-50 mg / day, even more preferably 5-18 mg / day, even more preferably 5-10 mg
/ Day.

As homocarnosine, 5-500 mg /
Day, preferably 10-200 mg / day, more preferably 5
To 200 mg / day, more preferably 5 to 50 mg / day, further preferably 5 to 18 mg / day, further preferably 5-1
It is 0 mg / day. Also, as π-methylhistidine 7.
It is 5 to 750 mg / day, preferably 15 to 300 mg / day, more preferably 7.5 to 300 mg / day, more preferably 7.5 to 15 mg / day.

Further, as τ-methylhistidine, 7.5 to
750 mg / day, preferably 15-300 mg / day, more preferably 7.5-300 mg / day, more preferably 7.5.
~ 15 mg / day. Anserine of the present invention, carnosine, barenin, homocarnosine, π-methylhistidine, τ-methylhistidine is a substance originally present in the living body, therefore, low toxicity and high safety, it is caused by a decrease in the number of red blood cells. It has great significance as a preventive or ameliorating agent for medical symptoms. For example, the safety of L-carnosine is as described in the paragraph of acute toxicity in JP-A-2-35057.

When the preventive or ameliorating agent for medical symptoms caused by a decrease in red blood cell count of the present invention is used in the form of food or drink, it may be in the form of the above-mentioned preparation, but the required amount of the anserine or carnosine of the present invention may be used. , Varenin, homocarnosine, π-
Methylhistidine, τ-methylhistidine or an extract containing these as the main ingredients is a food or drink raw material, especially carnosine, anserine, varenin, homocarnosine, π-methylhistidine, τ-methylhistidine is essentially a food or drink raw material that does not substantially contain In addition to the above, it can be processed and manufactured by a general manufacturing method. The blending amount varies depending on the dosage form and the morphological characteristics of the food, but is generally preferably 0.001 to 50%, but is not particularly limited.

In the present invention, foods and drinks which are substantially free of anserine, carnosine, valenin, homocarnosine, π-methylhistidine, τ-methylhistidine include beef, pork, chicken, fish, whale meat, snake meat, etc. Foods and drinks that do not use meat as a raw material and foods and drinks that do not use meat extracts such as beef, pork, chicken, fish, whale, and snake meat are listed as beef, pork, chicken, fish, whale meat. , Even in foods and drinks made from meat such as snake meat, anserine, carnosine, varenin, homocarnosine, π-methylhistidine, τ-methylhistidine because the product content is very small, anserine per serving, Carnosine, valenin, homocarnosine, π-methylhistidine, τ-methylhistidine having a total amount of less than 50 mg are anserine and carnosine of the present invention. Emissions, balenine, contained in homocarnosine, .pi.-methylhistidine, food essentially not containing the τ- methylhistidine.

As a form of food, an extract containing anserine, carnosine, valenin, homocarnosine, π-methylhistidine, τ-methylhistidine alone or in combination or containing an imidazole compound as a main component is used as a protein (as a protein source). Is a highly nutritious milk protein with high amino acid balance, soy protein, egg white oligopeptide, soy hydrolyzate, etc., as well as a mixture of single amino acids), sugars, fats, trace elements, vitamins, etc. ,
Blended with emulsifiers, flavors, etc., natural liquid food, semi-digested nutritional food and ingredient nutritional food, solid or liquid food or luxury food such as bread, noodles, rice, confectionery (biscuits, Agricultural foods such as cakes, candy, chocolate, Japanese sweets), tofu and its processed products, fermented foods such as sake, medicinal liquor, mirin, vinegar, soy sauce, miso, dressing, yogurt, ham, bacon, sausage, mayonnaise, etc. It can be in the form of agricultural foods, fishery products such as kamaboko, fried tempura, and rice paste, fruit juice drinks, soft drinks, sports drinks, alcoholic drinks, drinks such as tea, and the like.

In addition, preventive and amelioration of medical symptoms caused by a decrease in the number of red blood cells, that is, anemia that suppresses hematopoietic functions such as chemotherapeutic agents such as anticancer agents and anemia caused by radiation therapy,
Aplastic anemia, congenital anemia, renal anemia, myeloid anemia,
For the purpose of improving prevention of anemia associated with rheumatoid arthritis, and improving blood loss anemia after surgery, blood donation, postpartum, etc. under the management of a nutritionist based on a doctor's meal prescription, when cooking a hospital meal. It is also possible to add the powder of the imidazole compound of the present invention to any food, and give it to the patient in the form of a functional food prepared in situ. In addition, vitamins, hormones and other nutritional supplements, trace elements and iron compounds may be mixed into the food and drink of the present invention.

Further, the preventive or ameliorating agent for medical symptoms caused by a decrease in red blood cell count of the present invention is intended for anemia caused by a decrease in red blood cell count due to insufficient hematopoietic function or loss of blood. For the purpose of preventive improvement,
The total amount of the imidazole compound of the present invention is 5 per day.
0 mg or more, preferably 100 mg or more, more preferably 5
0 mg to 5 g, more preferably 100 mg to 2 g, more preferably 50 mg to 2 g, more preferably 50 mg to 500 m.
g, more preferably 50 mg to 180 mg, and even more preferably 50 mg to 100 mg is preferably orally ingested.

As anserine, the daily dose is 50 mg or more, preferably 100 mg or more, more preferably 50 mg or more.
5 g, more preferably 100 mg to 2 g, more preferably 50 mg to 2 g, more preferably 50 mg to 500 mg, further preferably 50 mg to 180 mg, further preferably 50
It is desirable to be ingested orally in the range of 100 mg to 100 mg.
Further, as carnosine, 50 mg or more per day, preferably 100 mg or more, more preferably 50 mg to 5 g, more preferably 100 mg to 2 g, more preferably 50 mg to 2
g, more preferably 50 mg to 500 mg, even more preferably 50 mg to 180 mg, still more preferably 50 mg to 100
It is recommended to be taken orally in the mg range.

Also, as homocarnosine, 50 per day
mg or more, preferably 100 mg or more, more preferably 50
mg-5 g, more preferably 100 mg-2 g, more preferably 50 mg-2 g, more preferably 50-500 mg, even more preferably 50-180 mg, even more preferably 50.
It is desirable to be ingested orally in the range of 100 mg. Also, as π-methylhistidine, 75 mg or more per day,
Preferably 150 mg or more, more preferably 75 mg to 7.
It is desirable to be orally ingested in the range of 5 g, more preferably 150 mg to 3 g, more preferably 75 mg to 3 g, and further preferably 75 mg to 150 mg.

Further, as τ-methylhistidine, 75 mg or more, preferably 150 mg or more, more preferably 75 mg to 7.5 g, more preferably 150 mg to 3 g per day,
More preferably 75 mg to 3 g, more preferably 75 mg to
It is desirable to be taken orally in the range of 150 mg. The present invention will be described in more detail with reference to the above examples, but the present invention is not limited thereto.

Embodiment 1 Anticancer drug Cyclophosphama
Anemia Preventive Effect in Id-administered Mice Cyclophosphamide (CY) was intravenously injected into 7-week-old C57BL / mice at a dose of 300 mg / kg. L-anserin (Ans) was subcutaneously administered at a dose of 100 mg / kg every day from the day of cyclophosphamide administration. 1, 3, 5, 7, 9 days after administration of cyclophosphamide (L-
On the 3rd, 5th, and 7th days of the anserine administration group, blood was collected from the orbital venous plexus of the mouse, and the number of red blood cells and the amount of hemoglobin were measured by an automatic hemocytometer. The experiment was conducted with 3 animals per group, and the results are shown as the average value ± standard deviation. In the CY-only administration group, the number of red blood cells and hemoglobin decreased, leading to anemia symptoms on the 3rd to 7th day of administration. On the other hand, in the group administered with L-anserin together with CY, the decrease of the red blood cell count and hemoglobin was suppressed on the 3rd to 7th day of administration, indicating that L-anserin is effective in preventing anemia caused by an anticancer agent. Was done.

[0042]

[Table 1]

Example 2. Anemia treatment in X-ray irradiated mice
Effect Seven-week-old C57BL / mouse was irradiated with 4.0 Gy of whole body. L-anserin was continuously 1 from the day of X-ray irradiation.
It was subcutaneously administered at a dose of 100 mg / kg for 0 days. Fourteen days after the X-ray irradiation, blood was collected from the mouse orbital venous plexus, and the number of red blood cells and the amount of hemoglobin were measured by an automatic hemocytometer. The experiment was carried out with 3 animals per group, and the results are shown as mean value ± standard deviation. The red blood cell count and hemoglobin decreased by X-ray irradiation were still low at 14 days after irradiation, but
-In the group administered with anserine, L-anserin was shown to be effective in the treatment of anemia caused by X-ray irradiation since it promoted recovery of red blood cell count and hemoglobin.

[0044]

[Table 2]

Example 3. The concentrated liquid of the broth discharged during the production of canned tuna was treated with an ultrafiltration membrane for separating it with a molecular weight of 10,000 to obtain a clarified liquid of a low molecular weight fraction. After the pH of the clarified liquid was adjusted to 2.2 with dilute hydrochloric acid, this liquid was passed through a column packed with MM81 type ion exchange resin manufactured by Beckman Co. to adsorb anserine and carnosine. Then, with the column kept warm at 57 ° C., 0.4N sodium citrate solution was flown to obtain a fraction containing anserine and carnosine. This was freeze-dried to obtain a dried product. The content of anserine or carnosine in the dried product was measured by an amino acid analyzer.
% And 12%.

Example 4. Lactose 50 parts, sucrose 39.8 parts,
Mix 5 parts of tragacanth gum and 0.2 parts of peppermint,
A solution prepared by dissolving 5 parts of anserine and 0.002 part of cupric chloride in 3.5 parts of distilled water was added to this and kneaded well.
Next, the above kneaded product was spread on a glass plate on which starch was sprayed with a rolling pin to form a sheet having a thickness of about 5 mm, which was punched out with a mold and dried to obtain a troche.

Example 5. Carnosine 2 on 100 parts flour
Parts, manganese chloride 0.001 parts, sucrose 4 parts, salt 1.1
Part, skim milk powder 2 parts, yeast 3 parts, yeast food 0.
After 8 parts and 67.2 parts of water were added and kneaded, 5 parts of oil and fat was further added and kneaded well. Primary fermentation was carried out at 28 ° C. for 90 minutes. Then, punching was performed, and after 28 minutes at 28 ° C., the mixture was packed in a mold and baked at 190 ° C. for 30 minutes to manufacture. Regarding the physical properties of the bread after baking, as a result of comparison with a product produced without adding carnosine, no difference was found in flavor and texture.

Example 6. 80 parts of pork and 1 part of anserine,
1 part of carnosine, 0.001 part of cupric chloride, 0.02 part of sodium nitrite, 2 parts of sodium chloride, 0.3 part of sodium pyrophosphate, 0.06 part of sodium ascorbate, 1 part of sucrose After salting for 72 hours, seasonings and spices were added and the mixture was cut to prepare a paste. After filling this kneaded meat in a casing, a sausage was produced according to a conventional method. As a result of a sensory test of this sausage, no difference in color tone, texture or flavor was observed as compared with sausage produced without adding anserine and carnosine.

Example 7. Granules were produced according to the following formulation using the synthesized anserine. Anserine 0.2 g Cupric chloride 0.02 mg Lactose 0.34 g Corn starch 0.45 g Hydroxypropyl methylcellulose 0.01 g

Example 8. To 20 g of vitamin C, 10 g of ferrous sulfate, 40 g of granulated sugar, and 30 g of an equal mixture of corn starch and lactose, 50 g of the extract obtained in Example 3 was added and mixed. The mixture was divided into 100 equal parts and packed in a bag to produce 100 bags of 1.5 g of a stick-shaped functional food having a red blood cell count reduction and mitigation effect.

Claims (9)

[Claims] 1. A medical method resulting from a decrease in the number of red blood cells containing one or more imidazole compounds selected from the group of anserine, carnosine, varenin, homocarnosine, π-methylhistidine, and τ-methylhistidine. Preventive or ameliorating agent for symptoms. 2. A food or drink substantially free of anserine, carnosine, valenin, homocarnosine, π-methylhistidine, and τ-methylhistidine, containing anserine,
Carnosine, valenin, homocarnosine, π-methylhistidine, and τ-methylhistidine at least one imidazole compound selected from the group, or by adding an extract containing this as a main component, to reduce the number of red blood cells A food or drink that has an action of preventing or ameliorating the resulting medical symptoms. 3. A method for producing a food or drink having an action of preventing or ameliorating a medical condition caused by a decrease in the number of red blood cells, which comprises anserine, carnosine, valenin, homocarnosine, π.
-Methylhistidine, and τ-methylhistidine substantially in the food and drink, anserine, carnosine, varenin, homocarnosine, π-methylhistidine, and τ
-A method comprising adding one or more imidazole compounds selected from the group of methylhistidine, or an extract containing this as a main component. 4. The preventive or ameliorating agent according to claim 1, wherein the medical symptom caused by the decrease in the red blood cell count is anemia of hematopoietic function inhibiting property. 5. The food or drink according to claim 2, wherein the medical symptom caused by the decrease in the number of red blood cells is anemia that suppresses hematopoietic function. 6. The method for producing a food or drink according to claim 3, wherein the medical symptom caused by the decrease in the number of red blood cells is anemia that suppresses hematopoietic function. 7. The preventive or ameliorating agent according to claim 1, wherein the medical condition caused by the decrease in the red blood cell count is blood loss anemia. 8. The food or drink according to claim 2, wherein the medical condition caused by the decrease in the number of red blood cells is blood loss anemia. 9. The method for producing a food or drink according to claim 3, wherein the medical condition caused by the decrease in the red blood cell count is blood loss anemia.